NCNA
Nucana·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NCNA
Nucana Plc
A company that develops and commercializes novel, plant-based protein ingredients for the food industry
Pharmaceutical
01/28/1997
09/28/2017
NASDAQ Stock Exchange
20
12-31
Depository Receipts (Ordinary Shares)
3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom
--
Nucana Plc is a private company registered in England and Wales as "Biomedical" (UK) Limited on 28 January 1997. The company is a clinical-stage biopharmaceutical company dedicated to significantly improving the therapeutic efficacy of cancer patients by applying pro tidal technology to convert some of the most widely available chemotherapeutic preparations, nucleoside analogues, into more effective and safer drugs. Although these traditional drugs are still part of the standard for the treatment of many solid tumors, their efficacy is limited by the resistance mechanisms of cancer cells and is often poorly tolerated. Using patented technology, the company is developing a new drug, protide, that aims to overcome key cancer resistance mechanisms and produce more anticancer metabolites in cancer cells.
Company Financials
EPS
NCNA has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected 0, meeting expectations. The chart below visualizes how NCNA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
